Cipla

29th November 2016

To,

(a) BSE Limited
Listing Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400 001

(b) National Stock Exchange of India Limited
Listing Department
Exchange Plaza, Bandra Kurla Complex
Bandra (E)
Mumbai-400 051

(c) SOCIETE DE LA BOURSE DE LUXEMBERG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Dear Sirs,

Please find enclosed Press Release titled as "Cipla appoints Ireena Vittal as an Independent Director on its Board".

Kindly acknowledge the receipt.

Thank you,

Yours faithfully,
For Cipla Limited

M. A. Sanghvi

Mital Sanghvi
Company Secretary

Encl: as above

Press Release

Cipla appoints Ireena Vittal as an Independent Director on its Board

Mumbai, November 29, 2016: Cipla Ltd, a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients, is delighted to announce the appointment of Ms. Ireena Vittal as an independent director on its Board with effect from December 1, 2016.

Ms. Vittal, a former partner with McKinsey & Company, is an MBA from Indian Institute of Management, Kolkata. She has over two decades of experience in management consulting and is recognised as a thought leader for consumer-facing companies in emerging markets. Prior to joining McKinsey, Ms. Vittal worked with Nestle and MaxTouch (now Vodafone). She has also served government and public institutions to design and implement solutions core to India's development, such as inclusive urban development and sustainable rural growth.

Welcoming her appointment as an independent director, Dr. Y. K. Hamied, Non-Executive Chairman, Cipla Limited said, "We are delighted to welcome Ms. Vittal to our Board. Cipla is in the midst of preparing itself for an exciting future and her background of both business and advisory will be very useful to the Company."

Ms. Ireena Vittal said, "I am honoured to have been invited to join the Board of one of India's most respected and iconic companies. These are very exciting times for Cipla as it transforms itself to be even more relevant to the millions of patients globally."

Ends

About Cipla Limited

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. In the last 80+ years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 100 countries. Our portfolio includes over 1000 products across wide range of therapeutic categories with one quality standard globally.

Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla's emphasis on access for patients was recognised globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than a dollar a day and thereby treating many millions of patients since 2001. Cipla's research and development focuses on developing innovative products and drug delivery systems.

Media Contacts:
Corporate Communications
Pallavi Golar
Mobile: +91 9833641788
E Mail: pallavi.golar@cipla.com